You are here: Home: CCU 3 | 2003: Norman Wolmark, MD: Select publications


Select publications

Publications discussed by Dr Wolmark

Benson AB et al. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO 2003;Abstract 975.

DeGramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized MOSAIC trial. Proc ASCO 2003;Abstract 1015.

Gamelin E et al. Prevention of oxaliplatin peripheral sensory neuropathy by Ca+ gluconate/Mg+ chloride infusions: A retrospective study. Proc ASCO 2002;Abstract 624.

Giantonio BJ et al. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as frontline therapy for advanced colorectal cancer (advCRC): Results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. Proc ASCO 2003;Abstract 1024.

Hurwitz H et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO 2003:Abstract 3646.

Smith RE et al. UFT/leucovorin vs 5-FU/leucovorin in colon cancer. Oncology (Huntingt) 2000;14(10 Suppl 9):24-7. Abstract

 

Table of Contents Top of Page

Home

Editor’s Note
 
Norman Wolmark, MD
- Select publications
 
John Zalcberg, MB, BS, PhD, FRACP
- Select publications
 
Yehuda Patt, MD
- Select publications
 
Lawrence D Wagman, MD, FACS
- Select publications

Faculty Disclosures

A CME Audio Series and Activity

Editor's office

 

Terms of use and general disclaimer
© NL Communications, Inc. 2003. All rights reserved.